Investigating a specific type of prostate cancer to find new treatment options
Official title: A study of IDH1-mutant prostate cancer to identify novel therapeutic targets
Funded at Johns Hopkins University · NIH-10947087 · Data updated 2026-11-12
This study is looking at a specific type of prostate cancer with a gene change that makes it tough to treat, and it's for patients with this mutation to help find better ways to manage their cancer and improve their treatment options.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Johns Hopkins University NIH-funded |
| Lab location | 1 site (Baltimore, United States) |
| Project start | July 1, 2024 |
| Project end | June 30, 2026 |
| Funding year | 2024 |
| Award (this year) | $421,042 |
| NIH project number | 1R21CA292179-01 |
| Project ID | NIH-10947087 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with metastatic prostate cancer who have the IDH1 mutation.
✕Less likely to help
Patients without the IDH1 mutation or those with other types of prostate cancer may not benefit from this research.
What this research studies
This research focuses on a rare subtype of prostate cancer that has a mutation in the IDH1 gene, which appears to resist common therapies. The team will explore how this mutation affects the cancer's ability to adapt to treatment and will investigate potential new therapeutic targets to prevent therapy resistance. By studying a large group of patients with this mutation, the researchers aim to understand the underlying mechanisms and improve treatment outcomes for affected individuals.
Why it matters
Potential benefit: If successful, this research could lead to new treatment strategies that prevent resistance in prostate cancer patients with IDH1 mutations.
How similar studies have gone: Previous research has shown that targeting IDH1 mutations in other cancers has been promising, suggesting potential for success in this area as well.
Where this research is happening
-
Johns Hopkins University
Baltimore, United States Active
Researchers
- Principal investigator: Sena, Laura a. — Johns Hopkins University
- Study coordinator: Sena, Laura a.
Related research
Other NIH-funded projects on the same topics.
-
Cardiovascular risk planning and reduction for men with prostate cancer
A program to better predict and reduce heart disease risk in men treated for prostate cancer, especially older patients.
-
Effects of ADT on motivation and emotion in prostate cancer patients
This project looks at how androgen deprivation therapy may affect motivation and mood over time in men with prostate cancer.
-
Causal Protein Markers to Understand and Predict Prostate Cancer Risk in Africans and Europeans
A cancer research project looking at proteins linked to prostate cancer to better understand why it happens and how risk differs between African and European populations.
-
Ethical multimodal AI platform to improve prostate cancer detection with ultrasound
A patient-friendly AI system uses ultrasound and MRI information to help doctors better find prostate cancer, aiming to improve accuracy and access.
-
Characterizing epigenetic targets in prostate cancer to help AR-driven cancer
A research project at MD Anderson aims to understand how epigenetic factors shape androgen receptor signaling in prostate cancer to find new ways to treat resistant forms of the disease.
-
AR and RNA-binding in prostate cancer resistance
A cancer research grant exploring how the androgen receptor’s interaction with RNA may drive treatment resistance in prostate cancer, with potential to guide new therapies.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.